Greetings all....I came across this article whilst browsing the...

Greetings all....I came across this article whilst browsing the Ninemsn site.....looks potentially promising for VLA and other biotechs.  GV is a 'Health Investment' arm of GOOGLE with 2.5 billion to invest.  VLA looks an ideal fit for them in my opinion.   We live in hope  !!!!!!!!!!!!!!!! Read this part of the article.................


When describing his vision for GV and the health-care areas he wants to invest in, Maris lists genomics, cancer, central nervous system disorders and aging, focusing on either technology or therapeutics. Maris’s targets include areas where drugmakers have struggled to find breakthroughs. Among age- related diseases, for example, there have been more than 100 attempts to develop an Alzheimer’s treatment since 1998, and all have failed. At the same time, any successful treatment would have multibillion-dollar markets.
‘Spectacular Outcomes’
“Often, the ones that are most controversial -- Uber, Foundation -- have the most spectacular outcomes, good or bad,” Maris said. “We are looking for spectacular outcomes. The most you can lose is all of your money.” The gains can be far larger, he said.
Despite Maris’s confidence, some of GV’s health companies have faced significant challenges. Foundation Medicine Inc., backed by GV since 2011, has been slow to get insurers to cover its genetic profiles of cancer tumors. The FDA stopped 23andMe Inc., a GV company since 2010, from providing health analysis along with its genetic-sequencing service for a year. While it’s now cleared to give consumers reports on carrier status for some genetic diseases, it’s a limited subset compared to what was previously offered.
As for Editas, it’s not yet known how regulators will approach a technology that can directly edit the human genome, or what price such a treatment could command if it works. GV declined to comment on whether it sold any of its stake in the IPO.
How those bets and others turn out will be the measure of whether GV is as savvy as traditional biotech venture firms that have more experience navigating the FDA, and can bring additional advantages as well. Gandhi, the former Rock Health managing director, said only time will show if Maris and GV’s strategy is the right one.
“It’s too early to tell if they have good bets in place,” he said.
Don't bail on biotech